Journals / Celal Bayar Üniversitesi Sağlık Bilimleri Enstitüsü Dergisi / 2023 / Cilt: 10 Sayı: 2

The Clinical, Laboratory, and Imaging Features of Children with Juvenile Dermatomyositis: A Single Center Experience

Juvenil Dermatomiyozit Tanısı ile Takipli Çocuk Hastaların Klinik, Laboratuvar ve Görüntüleme Bulgularının Değerlendirilmesi: Tek Merkez Deneyimi

Pages
76–82
Publication Date
2023-06-30
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Documenting existing patient data and presenting multidisciplinary data will be a guide for physicians who have undertaken the management of these patients.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Juvenile dermatomyositis (JDM) is a rare disease that accounts for the majority of idiopathic inflammatory myositis, typically affecting muscle and skin.
📊
Key Findings & Data:Materials and Methods: The patients' medical records followed up with the diagnosis of JDM for at least 6 months between 2015- 2021 and were evaluated retrospectively.
💡
Conclusion & Impact:Documenting existing patient data and presenting multidisciplinary data will be a guide for physicians who have undertaken the management of these patients.
🔬Design:Research Article
📍Scope:2015- 2021 Verileri
⚙️Variables:Juvenil dermatomiyozit · juvenil idiopatik inflamatuar miyopati · elektromiyografi

Abstract

Objective: Juvenile dermatomyositis (JDM) is a rare disease that accounts for the majority of idiopathic inflammatory myositis, typically affecting muscle and skin. Our study aims to evaluate pediatric patients' demographic, clinical, laboratory, and imaging characteristics and treatments followed up with the diagnosis of JDM in a tertiary pediatric rheumatology center. Materials and Methods: The patients' medical records followed up with the diagnosis of JDM for at least 6 months between 2015- 2021 and were evaluated retrospectively. Results: Six female and six male patients were included in the study. At the time of diagnosis, 5 patients had mild, 3 patients had moderate and 4 patients had severe clinical findings. During the follow-up, the clinical course was monocyclic in 2 patients, chronic persistent in 7 patients, and polycyclic in 3 patients. All patients had skin and muscle involvement at the time of diagnosis. At least one muscle enzyme elevation was found in 9 patients, CK elevation in 7 patients, LDH elevation in 7 patients, and AST elevation in 5 patients. Calcinosis was observed in 5 patients, joint contracture in 2 patients, and lipodystrophy in 1 patient during the follow-up period. High-dose methylprednisolone was given to 9 patients for 3 days as initial treatment. Seven (58.3) patients received IVIG. Conclusion: Managing JDM is difficult because of patients are followed by experienced multidisciplinary pediatric rheumatology centers. Documenting existing patient data and presenting multidisciplinary data will be a guide for physicians who have undertaken the management of these patients.

Özet

Giriş ve Amaç: Juvenil dermatomiyozit (JDM) idiyopatik inflamatuar miyozitlerin büyük çoğunluğunu oluşturan, kas ve cilt tutulumu ile seyreden nadir görülen bir otoimmün miyopatidir. Çalışmamızın amacı merkezimizde JDM tanısı ile takip edilen çocuk hastaların demografik, klinik, laboratuvar, görüntüleme özelliklerinin ve tedavilerinin değerlendirilmesidir. Gereç ve Yöntemler: Kliniğimizce 2015-2021 tarihleri arasında JDM tanısı ile en az 6 ay takip edilen hastaların verileri geriye yönelik olarak hasta tıbbi kayıtları incelenerek değerlendirildi. Bulgular: Çalışmaya 6 kız 6 erkek hasta dahil edildi. Başvuru sırasında 5 hasta hafif, 3 hasta orta, 4 hasta ağır klinik bulgular ile tanı aldı. Takip süresince klinik seyir 2 hastada monosiklik, 7 hastada kronik persistan ve 3 hastada polisiklikti. Tüm hastaların tanı sırasında cilt ve kas bulguları mevcuttu, laboratuvar olarak 9 hastada en az bir kas enzimi yüksekliği, 7 hastada CK yüksekliği, 7 hastada LDH yüksekliği ve 5 hastada AST yüksekliği vardı. Takip süresince 5 hastada kalsinozis, 2 hastada eklem kontraktürü ve 1 hastada lipodistrofi gelişimi gözlendi. Başlangıç tedavisi olarak 9 hastaya yoğun yüksek doz metilprednizolon 3 gün süre ile verildi. Takipte yedi (58,3) hastaya IVIG tedavisi verildi. Sonuç: JDM tedavisi ve takibi zor olan, multidisipliner deneyimli çocuk romatoloji merkezlerince yönetilen bir hastalıktır. Mevcut hasta verilerinin dökümente edilmesi ve multidisipliner verilerin sunulması bu hastaları takip eden hekimler için yol gösterici olacaktır.

🔖

Cite This Article

ÇAKMAK, F., DEMİRKAN, F. G., AYAZ, N. A. (2023). The Clinical, Laboratory, and Imaging Features of Children with Juvenile Dermatomyositis: A Single Center Experience. Celal Bayar Üniversitesi Sağlık Bilimleri Enstitüsü Dergisi, Cilt: 10 Sayı: 2, 76–82. https://ajindex.com/articles/951272

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Clarissa A. Pilkington BMF, Watchareewan Sontichai: Juvenile Dermatomyositis and Other Inflammatory Muscle Diseases. In: Textbook of Pediatric Rheumatology. edn. Edited by Ross E. Petty RML, Carol B. Lindsley, Lucy R. Wedderburn, Elizabeth D. Mellins, Robert C. Fuhlbrigge; 2021: 360-375
  2. McCann L, Juggins A, Maillard S, Wedderburn L, Davidson J, Murray K, Pilkington CJR: The Juvenile Dermatomyositis National Registry and Repository (UK and Ireland)—clinical characteristics of children recruited within the first 5 yr. 2006, 45(10):1255-1260
  3. Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, Flores-Suarez LF, Gross WL, Guillevin L, Hagen EC et al: 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis and rheumatism 2013, 65(1):1-11
  4. Robinson AB, Hoeltzel MF, Wahezi DM, Becker ML, Kessler EA, Schmeling H, Carrasco R, Huber AM, Feldman BM, Reed AM: Clinical characteristics of children with juvenile dermatomyositis: the Childhood Arthritis and Rheumatology Research Alliance Registry. Arthritis care & research 2014, 66(3):404-410
  5. Guseinova D, Consolaro A, Trail L, Ferrari C, Pistorio A, Ruperto N, Buoncompagni A, Pilkington C, Maillard S, Oliveira SK et al: Comparison of clinical features and drug therapies among European and Latin American patients with juvenile dermatomyositis. Clinical and experimental rheumatology 2011, 29(1):117-124
  6. Bohan A, Peter JB: Polymyositis and dermatomyositis (first of two parts). The New England journal of medicine 1975, 292(7):344-347
  7. Brown VE, Pilkington CA, Feldman BM, Davidson JE: An international consensus survey of the diagnostic criteria for juvenile dermatomyositis (JDM). Rheumatology (Oxford, England) 2006, 45(8):990-993
  8. Bitnum S, Daeschner CW, Jr., Travis LB, Dodge WF, Hopps HC: DERMATOMYOSITIS. The Journal of pediatrics 1964, 64:101-131
  9. Huber AM, Feldman BM, Rennebohm RM, Hicks JE, Lindsley CB, Perez MD, Zemel LS, Wallace CA, Ballinger SH, Passo MH et al: Validation and clinical significance of the Childhood Myositis Assessment Scale for assessment of muscle function in the juvenile idiopathic inflammatory myopathies. Arthritis and rheumatism 2004, 50(5):1595-1603
  10. Mathiesen PR, Zak M, Herlin T, Nielsen SM: Clinical features and outcome in a Danish cohort of juvenile dermatomyositis patients. Clinical and experimental rheumatology 2010, 28(5):782-789
  11. Mathiesen P, Hegaard H, Herlin T, Zak M, Pedersen FK, Nielsen S: Long-term o